טוען...
The Anticipated Next Season of EGFR Inhibitors
EGFR-directed therapy in lung cancer is here to stay, with new drugs targeting T790M-mediated resistance coming quickly and the field continuing to advance. With greater access to sophisticated tools for interrogating both the somatic and germline genome, and with widespread acceptance of the scient...
שמור ב:
| הוצא לאור ב: | Oncologist |
|---|---|
| מחבר ראשי: | |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AlphaMed Press
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4391775/ https://ncbi.nlm.nih.gov/pubmed/25795633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0086 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|